Type 2 Diabetes in PracticeType 2 Diabetes in Practice

An Expert Commentary With An Expert Commentary With Clifford J. Bailey, PhDClifford J. Bailey, PhD

A Clinical Context ReportA Clinical Context Report

Jointly Sponsored by:Jointly Sponsored by:

andand

Clinical Context: Type 2 Diabetes in PracticeClinical Context: Type 2 Diabetes in PracticeExpert CommentaryExpert Commentary

This activity is supported by an independent This activity is supported by an independent educational grant from educational grant from

Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim Pharmaceuticals, Inc. which was made possible, in part, through a which was made possible, in part, through a

collaboration with Eli Lilly and Company.collaboration with Eli Lilly and Company.

Clinical Context: Type 2 Diabetes in PracticeClinical Context: Type 2 Diabetes in PracticeExpert CommentaryExpert Commentary

Type 2 Diabetes in PracticeType 2 Diabetes in PracticeClinical Context SeriesClinical Context Series

The goal of this series is to provide up-to-The goal of this series is to provide up-to-date information and multiple perspectives date information and multiple perspectives on the pathogenesis, patient identification, on the pathogenesis, patient identification, symptoms, risk factors, and current and symptoms, risk factors, and current and emerging treatments and best practices in emerging treatments and best practices in the management of type 2 diabetesthe management of type 2 diabetes.

Type 2 Diabetes in PracticeType 2 Diabetes in PracticeClinical Context SeriesClinical Context Series

Target AudienceTarget Audience

Endocrinologists, cardiologists, diabetes Endocrinologists, cardiologists, diabetes educators, primary care physicians, educators, primary care physicians, nurses, nurse practitioners, physician nurses, nurse practitioners, physician assistants, pharmacists, and other assistants, pharmacists, and other healthcare professionals involved in the healthcare professionals involved in the care of patients with type 2 diabetes.care of patients with type 2 diabetes.

Activity Activity Learning ObjectiveLearning Objective

Upon successful completion of this Upon successful completion of this educational program, participants should educational program, participants should be able to:be able to:

Review the relevance and significance of the Review the relevance and significance of the activity in the broader context of clinical care.activity in the broader context of clinical care.

CME Information: PhysiciansCME Information: Physicians

Statement of AccreditationStatement of Accreditation

This activity has been planned and implemented This activity has been planned and implemented in accordance with the Essential Areas and in accordance with the Essential Areas and Policies of the Accreditation Council for Policies of the Accreditation Council for Continuing Medical Education through the joint Continuing Medical Education through the joint sponsorship of the Projects In Knowledge and sponsorship of the Projects In Knowledge and MedPage Today. Projects In Knowledge is MedPage Today. Projects In Knowledge is accredited by the ACCME to provide continuing accredited by the ACCME to provide continuing medical education for physicians. medical education for physicians.

CME InformationCME Information

Credit DesignationCredit Designation

Projects In Knowledge designates this Projects In Knowledge designates this enduring material for a maximum of 0.5 enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.™ AMA PRA Category 1 Credits.™

Physicians should claim only the credit Physicians should claim only the credit commensurate with the extent of their commensurate with the extent of their participation in the activity.participation in the activity.

CME Information: PhysiciansCME Information: Physicians

Credit for Family PhysiciansCredit for Family Physicians

MedPage Today "News-Based CME" has been MedPage Today "News-Based CME" has been reviewed and is acceptable for up to 2098 reviewed and is acceptable for up to 2098 Elective credits by the American Academy of Elective credits by the American Academy of Family Physicians. AAFP accreditation begins Family Physicians. AAFP accreditation begins January 1, 2011. Term of approval is for one January 1, 2011. Term of approval is for one year from this date. Each article is approved year from this date. Each article is approved for 0.5 Elective credits. Credit may be claimed for 0.5 Elective credits. Credit may be claimed for one year from the date of each article. for one year from the date of each article.

CE Information: NursesCE Information: Nurses Statement of AccreditationStatement of Accreditation

– Projects In Knowledge, Inc. (PIK) is accredited as a Projects In Knowledge, Inc. (PIK) is accredited as a provider of continuing nursing education by the provider of continuing nursing education by the American Nurses Credentialing Center’s Commission American Nurses Credentialing Center’s Commission on Accreditation.on Accreditation.

– Projects In Knowledge is also an approved provider by Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider the California Board of Registered Nursing, Provider Number CEP-15227.Number CEP-15227.

– This activity is approved for 0.50 nursing contact This activity is approved for 0.50 nursing contact hours.hours.

– There is no fee for this activity.There is no fee for this activity.

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: PharmacistsCE Information: Pharmacists

Projects In KnowledgeProjects In Knowledge®® is accredited by the is accredited by the Accreditation Council for Pharmacy Education Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy (ACPE) as a provider of continuing pharmacy education. This program has been planned and education. This program has been planned and implemented in accordance with the ACPE Criteria implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This activity for Quality and Interpretive Guidelines. This activity is worth up to 0.5 contact hours (0.05 CEUs). The is worth up to 0.5 contact hours (0.05 CEUs). The ACPE Universal Activity Number assigned to this ACPE Universal Activity Number assigned to this knowledge-type activity is 0052-9999-11-1779-H04-knowledge-type activity is 0052-9999-11-1779-H04-P.P.

Clifford J. Bailey, PhD

Professor of Clinical Medicine

Aston University

Department of Life & Health Sciences

Birmingham, UK

DiscussantDiscussant

Disclosure InformationDisclosure Information

Clifford J. Bailey, PhD,

disclosed the following relevant financial relationships:disclosed the following relevant financial relationships:

Board Member/Advisory Panel: Board Member/Advisory Panel: Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Merck Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme Limited; Novo Nordisk; Roche Pharmaceuticals.Sharp & Dohme Limited; Novo Nordisk; Roche Pharmaceuticals.

Research Support: Research Support: sanofi-aventis.sanofi-aventis.

Disclosure InformationDisclosure InformationDori F. Zaleznik, MD, Associate Clinical Professor of Medicine, Harvard Medical School, Boston; Crystal Phend; andand Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner, have disclosed that they have no relevant have disclosed that they have no relevant financial relationships or conflicts of interest with commercial financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational interests related directly or indirectly to this educational activity.activity.

The staffs of Projects In Knowledge andand MedPage Today have no relevant financial relationships or conflicts of interest have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this with commercial interests related directly or indirectly to this educational activity.educational activity.

Type 2 Diabetes Global Prevalence

• More than doubled worldwide from 1980 to 2008

— From 8.3% to 9.8% among adult men

— From 7.5% to 9.2% among adult women

Source: Danaei G, et al Lancet 2011; 378: 31-40.

Microvascular Risk Reduction With Better Glycemic Control

• United Kingdom Prospective Diabetes Study (UKPDS)— Each percentage point decrease in hemoglobin

A1c reduced microvascular complication risk by 35%

• Diabetes Control and Complications Trial (DCCT) — A two-percentage point reduction in hemoglobin

A1c cut occurrence of microvascular complications by 39% to 76%

Sources: UKPDS Group Lancet 1998; 352: 837-853.DCCT Research Group N Engl J Med 1993; 329: 977-986.

Recent Trials of More Intensive Glucose Control

• Mean diabetes duration at baseline:

— Action to Control Cardiovascular Risk in Diabetes (ACCORD) – 10 years

— Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) – 8 years

— Veterans Affairs Diabetes Trial (VADT) – 11.5 years

Sources:ACCORD Study Group N Engl J Med 2008; 358: 2545-2559.ADVANCE Collaborative Group N Engl J Med 2008; 358: 2560-2572. Duckworth W, et al N Engl J Med 2009; 360: 129-139.

Early Start Matters

• UKPDS – Micro- and macrovascular benefits from more intensive glucose management in newly diagnosed type 2 diabetes

• VADT – No micro- or macrovascular benefits from more intensive glucose management in advanced type 2 diabetes

Sources:Holman RR, et al N Engl J Med 2008; 359: 1577-1589.Holman RR, et al N Engl J Med 2008; 359: 1565-1576.Duckworth W, et al N Engl J Med 2009; 360: 129-139.

Once-Weekly Exenatide (Bydureon)

• Extended release formulation of twice-daily exenatide (Byetta)

• FDA approval declined in October 2010

• European Medicines Agency granted approval in June 2011

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

• Sitagliptin (Januvia)

• Saxagliptin (Onglyza)

• Linagliptin (Tradjenta) – Approved by FDA in May 2011

G-Protein-Coupled Receptor Stimulation

• Raises GLP-1 levels indirectly

• Oral delivery

• Early phase research

Type 2 diabetes prevalence is on the rise, bringing with it a pending tide of cardiovascular complications

Deterioration of beta-cell function contributes to progression of type 2 diabetes, which often is marked by worsening insulin resistance as well. Both processes are typically well under way by the time of diagnosis

Summary

At the end of this activity, participants should understand:

Better glycemic control is linked to reduced risk of microvascular disease and, over the long term, lower risk of macrovascular disease as well

Early intervention is key to these effects, as the ACCORD, VADT, and other trials have shown that more intensive efforts are largely ineffective later in the course of type 2 diabetes

Animal studies have suggested that very early use of incretin drugs can delay beta-cell decline

Summary

Incretin mimetics new to the clinic and on the horizon include the DPP-4 inhibitor linagliptin, which was approved by the FDA earlier this year, and a once-weekly formulation of the GLP-1 receptor agonist drug exenatide recently approved in Europe that is under review in the U.S.

A novel class of oral drugs that raise GLP-1 indirectly through G-protein-coupled receptor stimulation is in early stage development

Summary